Groupama Asset Managment Reduces Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Groupama Asset Managment lessened its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 45.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 126,880 shares of the medical research company's stock after selling 104,400 shares during the period. Groupama Asset Managment's holdings in Thermo Fisher Scientific were worth $65,830,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Howard Capital Management Group LLC lifted its holdings in Thermo Fisher Scientific by 0.5% during the 3rd quarter. Howard Capital Management Group LLC now owns 54,575 shares of the medical research company's stock valued at $33,759,000 after purchasing an additional 286 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in shares of Thermo Fisher Scientific by 22.1% during the 3rd quarter. Principal Financial Group Inc. now owns 1,247,838 shares of the medical research company's stock worth $771,876,000 after buying an additional 225,568 shares during the period. Fred Alger Management LLC bought a new position in Thermo Fisher Scientific in the 3rd quarter valued at about $1,274,000. Tradition Wealth Management LLC lifted its position in Thermo Fisher Scientific by 3.1% during the third quarter. Tradition Wealth Management LLC now owns 1,128 shares of the medical research company's stock worth $697,000 after acquiring an additional 34 shares during the last quarter. Finally, Cobblestone Capital Advisors LLC NY grew its position in shares of Thermo Fisher Scientific by 14.6% in the third quarter. Cobblestone Capital Advisors LLC NY now owns 783 shares of the medical research company's stock valued at $484,000 after purchasing an additional 100 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Remove Ads

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Citigroup reduced their price target on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. UBS Group raised their price target on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a "buy" rating in a research report on Friday, January 31st. Morgan Stanley boosted their price objective on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a report on Friday, January 31st. Scotiabank lifted their price target on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a "sector perform" rating in a research report on Monday, February 3rd. Finally, Royal Bank of Canada set a $693.00 price target on shares of Thermo Fisher Scientific in a report on Friday, January 31st. Four analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $653.23.

Thermo Fisher Scientific Stock Down 3.9 %

Shares of Thermo Fisher Scientific stock traded down $19.18 during trading on Thursday, reaching $469.88. 2,812,372 shares of the company traded hands, compared to its average volume of 1,631,024. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The firm has a market capitalization of $177.27 billion, a PE ratio of 28.43, a P/E/G ratio of 2.99 and a beta of 0.79. The company has a 50 day moving average price of $536.85 and a 200-day moving average price of $549.69. Thermo Fisher Scientific Inc. has a 1-year low of $468.39 and a 1-year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.37%. The ex-dividend date is Friday, March 14th. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's payout ratio is 10.41%.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 3,775 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the transaction, the senior vice president now owns 10,816 shares of the company's stock, valued at $5,759,736.32. The trade was a 25.87 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the transaction, the chief executive officer now owns 115,174 shares in the company, valued at approximately $59,506,950.58. This trade represents a 7.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 23,900 shares of company stock valued at $13,106,062. Corporate insiders own 0.34% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.